CheckEmoji Community · the emoji forum
🏠 Home 🆕 What's new ❓ Unanswered 🔥 Popular 📡 RSS Members 👥 0 online log in · register
Home › Gregory Fox48 › Posts

Posts by Gregory Fox48

2 posts shown.

Keith Wilson said:From the Mayo Clinic website (

"Vaccine efficacy was tested in 2,260 individuals aged 12 to 15, following a pediatric investigation plan (PIP) approved by the American Academy of Pediatrics at the FDA."

So, based on this, it’s unclear if those 2,000 kids were actually tested here in the US or if they just repackaged FDA data. Anyone know someone in the States whose kid was part of this trial?

"The study showed that the immune response to the Pfizer-BioNTech vaccine in this group was comparable to the immune response in the 16 to 25 age group (measured by SARS-CoV-2 antibody levels). Efficacy was calculated in approximately 2,000 children aged 12 to 15 who had no prior symptoms of COVID-19 infection. Half of the participants received the vaccine, while the other half received a placebo. None of the 1,005 people who received the vaccine developed COVID-19 symptoms, compared to 16 out of 978 participants who received the placebo. This means the vaccine demonstrated an efficacy of 100% in preventing COVID-19 disease (though the actual rate could be between 75% and 100%)."

First, they claim efficacy was measured via antibody levels, then they say they selected a sample of those without symptoms—shouldn't they have measured antibodies before the shot too?—only to conclude efficacy based on symptoms that, in kids, feel just like a common cold...

If that's not how it works, why aren't they being more precise? Are we just supposed to assume we're too dim to grasp scientific research, so they give us these oversimplified versions...

Keep in mind that 2,260 is the total number of participants, which includes both the experimental group and the control group. The actual experimental group consisted of only 1,131 people; the rest made up the control group, who receive a placebo instead of the vaccine itself.
Keith Wilson said:Quick question if anyone knows how this actually works. Did the folks over at Sony Music run any actual tests on small American groups—like what kind of sample size or methodology were they using? Or did they just shuffle some paperwork around, mix a few test tubes together, and decide it was good enough to pass?
Thanks.

I have some information here—not regarding Sony Music, specifically, but regarding the trials Pfizer used to get authorization from the FDA.

https://www.pfizer.com/news/press-re...esults-pivotal

https://www.fda.gov/news-events/pres...-emergency-use

Based on what I’m seeing above, this vaccine was authorized for emergency use (meaning it wasn't fully approved, just cleared for an emergency rollout) based on a clinical trial that only included 1,131 children in the experimental group. To put that into perspective: if this vaccine hypothetically carried a mortality risk of 1 in 2,000, a trial of that size would have a 43% chance of failing to detect it. And yet, based on a study that small, we are vaccinating hundreds of thousands of children against a disease that poses almost zero statistical threat to them.

Fortunately, I don't have kids in that age bracket, but the whole logic seems fundamentally broken to me. Why expose children to an experimental vaccine when the disease itself poses virtually no danger to them? The argument is always: "But they can spread it." To whom? From what I can see, either other children or adults. Other children aren't at risk, and adults can just get vaccinated themselves. That leaves only the vulnerable adults who, for various health reasons, cannot be vaccinated. So, the conclusion is that we should expose the entire pediatric population to the risks of an experimental shot just to protect a negligible number of adults who are already medically compromised. Someone put it well: we adults are here to protect the children, not the other way around.